Back to 2026 ePosters
Ensemble CMC Arthroplasty Shows Promising Short-Term Outcomes for Basal Thumb Arthritis
Naem Anthony Mufarreh, DO
1, Michael R McDermott, DO
1, Alex Davis, DO
2, Kyle Kaster, DO
1; H Brent Bamberger, DO
3(1)Kettering Health Grandview, Dayton, OH, (2)Ohio University College of Osteopathic Medicine, Athens, OH, (3)Grandview Medical Center, Dayton, OH
BACKGROUND: Thumb carpometacarpal (CMC) arthritis is a common degenerative condition that significantly impacts hand function and quality of life. Surgical intervention, including CMC arthroplasty, is often indicated for patients with persistent pain and functional limitations despite conservative management. The Ensemble CMC implant is a newer implant designed to improve pain relief, restore thumb mobility, and enhance patient outcomes. However, data on its short-term clinical effectiveness remains limited. This study aims to evaluate the early postoperative outcomes of patients undergoing CMC arthroplasty with the Ensemble CMC implant.
METHODS: A retrospective review was conducted on consecutive patients who underwent carpometacarpal (CMC) arthroplasty with the Ensemble CMC implant to evaluate short-term outcomes. Inclusion criteria required a minimum follow-up of one month. Patient demographics, surgical details, and postoperative course were obtained through chart review. Outcomes were assessed using Visual Analog Scale (VAS) pain scores and the abbreviated Disabilities of the Arm, Shoulder, and Hand (QuickDASH) questionnaire preoperatively and at the latest follow-up. Paired t-tests were used for statistical analysis.
RESULTS: Twenty-eight patients underwent CMC arthroplasty with the Ensemble CMC implant, with two patients receiving a second implantation in the opposite hand two months after their initial procedure, resulting in a total of 30 procedures. The average patient age was 59.7 ± 6.4 years, with a mean BMI of 34.4 ± 8.6 kg/m². Most patients were female (80%), and implant placement was evenly distributed between left and right hands (15 each). The average operative time was 35.9 ± 14.2 minutes (range: 17-84 minutes). The small implant size was the most frequently used (60%), followed by the medium (23.3%) and the large (16.7%). The mean follow-up period was 3.4 ± 2.4 months (range: 1.1-11.5 months). Pain scores significantly decreased from 6.9 ± 2.2 preoperatively to 1.7 ± 2.2 at final follow-up (p < 0.001). Functional improvement was also observed, with QuickDASH scores improving from 53.9 ± 18.6 to 38.4 ± 16.6 (p = 0.033). No revision surgeries were required in this cohort.
DISCUSSION: CMC arthroplasty with the Ensemble CMC implant is a quick, efficient procedure that significantly improves pain and function, with no major postoperative complications in this cohort. Patients experienced substantial pain reduction and improved QuickDASH scores, indicating improved hand function. Despite the limited follow-up period, early outcomes suggest the Ensemble CMC implant is a promising option for managing CMC arthritis.
Back to 2026 ePosters
